Airway delivery of an adenovirus-based ebola virus vaccine bypasses existing immunity to homologous adenovirus in nonhuman primates

Journal of Virology

Volumn 87, Issue 7, 2013, Pages 3668-3677

  Richardson, Jason S ^a   Pillet, Stéphane ^a,c   Bello, Alexander J ^a,b   Kobinger, Gary P ^a  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VACCINE; ADHU5 BASED VACCINE; ALPHA INTERFERON; EBOLA VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADENOVIRUS; AIRWAY DRUG DELIVERY SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EBOLA VIRUS; FEMALE; GUINEA PIG; IMMUNE RESPONSE; IMMUNITY; MACACA FASCICULARIS; MORTALITY; MOUSE; NONHUMAN; PRIMATE; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; SEROTYPE; SURVIVAL RATE; VIRUS REPLICATION; VIRUS STRAIN;

ADENOVIRIDAE; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; EBOLA VACCINES; EBOLAVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEMORRHAGIC FEVER, EBOLA; INJECTIONS, INTRAMUSCULAR; MACACA FASCICULARIS;

ADENOVIRIDAE; CAVIA; EBOLA VIRUS; MUS; PRIMATES;

EID: 84875525572     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02864-12     Document Type: Article

References (54)

1. Wilson JA, Bosio CM, Hart MK. 2001. Ebola virus: the search for vaccines and treatments. Cell. Mol. Life Sci. 58:1826-1841.
2. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, Ksiazek T, Johnson KM, Meyerhoff A, O'Toole T, Ascher MS, Bartlett J, Breman JG, Eitzen EM, Jr, Hamburg M, Hauer J, Henderson DA, Johnson RT, Kwik G, Layton M, Lillibridge S, Nabel GJ, Osterholm MT, Perl TM, Russell P, Tonat K. 2002. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 287: 2391-2405.
3. Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S. 2005. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 23:3033-3042.
4. Warfield KL, Bosio CM, Welcher BC, Deal EM, Mohamadzadeh M, Schmaljohn A, Aman MJ, Bavari S. 2003. Ebola virus-like particles protect from lethal Ebola virus infection. Proc. Natl. Acad. Sci. U. S. A. 100:15889-15894.
5. Warfield KL, Olinger G, Deal EM, Swenson DL, Bailey M, Negley DL, Hart MK, Bavari S. 2005. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J. Immunol. 175:1184-1191.
6. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, Bavari S. 2007. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J. Infect. Dis. 196(Suppl. 2): S430-S437.
7. Feldmann H, Jones S, Klenk HD, Schnittler HJ. 2003. Ebola virus: from discovery to vaccine. Nat. Rev. Immunol. 3:677-685.
8. Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Moller P, Wagner R, Volchkov V, Klenk HD, Feldmann H, Stroher U. 2004. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J. Virol. 78:5458-5465.
9. Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, Grolla A, Feldmann H. 2009. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of Ebola virus. J. Virol. 83:7296-7304.
10. Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, Daddario KM, Hensley LE, Jahrling PB, Geisbert TW. 2005. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11:786-790.
11. Qiu X, Fernando L, Alimonti JB, Melito PL, Feldmann F, Dick D, Stroher U, Feldmann H, Jones SM. 2009. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong Ebola GP-specific immune responses. PLoS One 4:e5547. doi: 10.1371/journal.pone.0005547.
12. Bukreyev A, Rollin PE, Tate MK, Yang L, Zaki SR, Shieh WJ, Murphy BR, Collins PL, Sanchez A. 2007. Successful topical respiratory tract immunization of primates against Ebola virus. J. Virol. 81:6379-6388.
13. Bukreyev A, Yang L, Zaki SR, Shieh WJ, Rollin PE, Murphy BR, Collins PL, Sanchez A. 2006. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J. Virol. 80:2267-2279.
14. Yang L, Sanchez A, Ward JM, Murphy BR, Collins PL, Bukreyev A. 2008. A paramyxovirus-vectored intranasal vaccine against Ebola virus is immunogenic in vector-immune animals. Virology 377:255-264.
15. Croyle MA, Patel A, Tran KN, Gray M, Zhang Y, Strong JE, Feldmann H, Kobinger GP. 2008. Nasal delivery of an adenovirus-based vaccine bypasses preexisting immunity to the vaccine carrier and improves the immune response in mice. PLoS One 3:e3548. doi:10.1371/journal.pone .0003548.
16. Patel A, Zhang Y, Croyle M, Tran K, Gray M, Strong J, Feldmann H, Wilson JM, Kobinger GP. 2007. Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice. J. Infect. Dis. 196(Suppl. 2):S413-S420.
17. Richardson JS, Yao MK, Tran KN, Croyle MA, Strong JE, Feldmann H, Kobinger GP. 2009. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS One 4:e5308. doi:10.1371/journal.pone.0005308.
18. Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, Lamoreaux L, Custers JH, Popernack PM, Yang ZY, Pau MG, Roederer M, Koup RA, Goudsmit J, Jahrling PB, Nabel GJ. 2006. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med. 3:e177. doi:10.1371/journal .pmed.0030177.
19. Nazir SA, Metcalf JP. 2005. Innate immune response to adenovirus. J. Investig. Med. 53:292-304.
20. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. 2000. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408:605-609.
21. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, O'Brien KL, Carville A, Mansfield KG, Goudsmit J, Havenga MJ, Barouch DH. 2007. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J. Virol. 81: 4654-4663.
22. Nwanegbo E, Vardas E, Gao W, Whittle H, Sun H, Rowe D, Robbins PD, Gambotto A. 2004. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin. Diagn. Lab. Immunol. 11:351-357.
23. Gallo P, Dharmapuri S, Cipriani B, Monaci P. 2005. Adenovirus as vehicle for anticancer genetic immunotherapy. Gene Ther. 12(Suppl. 1): S84-S91.
24. Nanda A, Lynch DM, Goudsmit J, Lemckert AA, Ewald BA, Sumida SM, Truitt DM, Abbink P, Kishko MG, Gorgone DA, Lifton MA, Shen L, Carville A, Mansfield KG, Havenga MJ, Barouch DH. 2005. Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vectorbased vaccines in mice and rhesus monkeys. J. Virol. 79:14161-14168.
25. Capone S, Meola A, Ercole BB, Vitelli A, Pezzanera M, Ruggeri L, Davies ME, Tafi R, Santini C, Luzzago A, Fu TM, Bett A, Colloca S, Cortese R, Nicosia A, Folgori A. 2006. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques. J. Virol. 80:1688-1699.
26. Kobinger GP, Feldmann H, Zhi Y, Schumer G, Gao G, Feldmann F, Jones S, Wilson JM. 2006. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 346:394-401.
27. Singh N, Pandey A, Jayashankar L, Mittal SK. 2008. Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of preexisting immunity against human adenovirus. Mol. Ther. 16:965-971.
28. Arvin AM, Greenberg HB. 2006. New viral vaccines. Virology 344:240-249.
29. Basset C, Holton J, O'Mahony R, Roitt I. 2003. Innate immunity and pathogen-host interaction. Vaccine 21(Suppl. 2):S12-S23.
30. Boyaka PN, Tafaro A, Fischer R, Leppla SH, Fujihashi K, McGhee JR. 2003. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J. Immunol. 170:5636-5643.
31. Lajeunesse M, Zhang Q, Finn A. 2004. Mucosal immunity to infections and its importance in future vaccinology. Adv. Exp. Med. Biol. 549:13-22.
32. Richardson JS, Abou MC, Tran KN, Kumar A, Sahai BM, Kobinger GP. 2011. Impact of systemic or mucosal immunity to adenovirus on Adbased Ebola virus vaccine efficacy in guinea pigs. J. Infect. Dis. 204(Suppl. 3):S1032-S1042.
33. Zhou D, Ertl HC. 2006. Therapeutic potential of adenovirus as a vaccine vector for chronic virus infections. Expert Opin. Biol. Ther. 6:63-72.
34. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, Roederer M, Koup RA, Jahrling PB, Nabel GJ. 2003. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424:681-684.
35. Richardson JS, Wong G, Pillet S, Schindle S, Ennis J, Turner J, Strong JE, Kobinger GP. 2011. Evaluation of different strategies for postexposure treatment of ebola virus infection in rodents. J. Bioterrorism Biodefense S1:007. doi:10.4172/2157-2526.S1-007.
36. Hoenen T, Groseth A, Kolesnikova L, Theriault S, Ebihara H, Hartlieb B, Bamberg S, Feldmann H, Stroher U, Becker S. 2006. Infection of naive target cells with virus-like particles: implications for the function of Ebola virus VP24. J. Virol. 80:7260-7264.
37. Nakayama E, Yokoyama A, Miyamoto H, Igarashi M, Kishida N, Matsuno K, Marzi A, Feldmann H, Ito K, Saijo M, Takada A. 2010. Enzyme-linked immunosorbent assay for detection of filovirus speciesspecific antibodies. Clin. Vaccine Immunol. 17:1723-1728.
38. Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, Addo MM, Lockman S, Peter T, Peyerl FW, Kishko MG, Jackson SS, Gorgone DA, Lifton MA, Essex M, Walker BD, Goudsmit J, Havenga MJ, Barouch DH. 2005. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 174:7179-7185.
39. Hidajat R, Kuate S, Venzon D, Kalyanaraman V, Kalisz I, Treece J, Lian Y, Barnett SW, Robert-Guroff M. 2010. Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains. Vaccine 28: 3963-3971.
40. Pushko P, Bray M, Ludwig GV, Parker M, Schmaljohn A, Sanchez A, Jahrling PB, Smith JF. 2000. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 19:142-153.
41. Sullivan NJ, Martin JE, Graham BS, Nabel GJ. 2009. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat. Rev. Microbiol. 7:393-400.
42. Wilson JA, Hart MK. 2001. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J. Virol. 75: 2660-2664.
43. Xu L, Sanchez A, Yang Z, Zaki SR, Nabel EG, Nichol ST, Nabel GJ. 1998. Immunization for Ebola virus infection. Nat. Med. 4:37-42.
44. Qiu X, Audet J, Wong G, Pillet S, Bello A, Cabral T, Strong JE, Plummer F, Corbett CR, Alimonti JB, Kobinger GP. 2012. Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci. Transl. Med. 4:138ra81. doi:10.1126/scitranslmed .3003876.
45. Kiyono H, Fukuyama S. 2004. NALT-versus Peyer's-patch-mediated mucosal immunity. Nat. Rev. Immunol. 4:699-710.
46. Hashimoto M, Boyer JL, Hackett NR, Wilson JM, Crystal RG. 2005. Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting antihuman adenovirus immunity. Infect. Immun. 73:6885-6891.
47. Santosuosso M, McCormick S, Xing Z. 2005. Adenoviral vectors for mucosal vaccination against infectious diseases. Viral Immunol. 18:283-291.
48. Xiang ZQ, Gao GP, Reyes-Sandoval A, Li Y, Wilson JM, Ertl HC. 2003. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J. Virol. 77:10780-10789.
49. Zhou D, Cun A, Li Y, Xiang Z, Ertl HC. 2006. A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus. Mol. Ther. 14:662-672.
50. Mohamadzadeh M, Chen L, Schmaljohn AL. 2007. How Ebola and Marburg viruses battle the immune system. Nat. Rev. Immunol. 7:556-567.
51. Klessig DF, Grodzicker T. 1979. Mutations that allow human Ad2 and Ad5 to express late genes in monkey cells map in the viral gene encoding the 72K DNA binding protein. Cell 17:957-966.
52. Qureshi H, Ma ZM, Huang Y, Hodge G, Thomas MA, DiPasquale J, DeSilva V, Fritts L, Bett AJ, Casimiro DR, Shiver JW, Robert-Guroff M, Robertson MN, McChesney MB, Gilbert PB, Miller CJ. 2012. Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine. J. Virol. 86:2239-2250.
53. Lemiale F, Kong WP, Akyurek LM, Ling X, Huang Y, Chakrabarti BK, Eckhaus M, Nabel GJ. 2003. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J. Virol. 77:10078-10087.
54. Brunetti-Pierri N, Palmer DJ, Beaudet AL, Carey KD, Finegold M, Ng P. 2004. Acute toxicity after high-dose systemic injection of helperdependent adenoviral vectors into nonhuman primates. Hum. Gene Ther. 15:35-46.